Lymphocyte P-glycoprotein variability in healthy individuals

Area of Science:

• Immunology
• Pharmacology
• Flow Cytometry

Background:

• P-glycoprotein (P-gp) is a crucial efflux transporter involved in drug pharmacokinetics.
• Understanding P-gp activity in lymphocytes is vital for personalized medicine.
• Previous studies have not fully characterized P-gp activity distribution in healthy populations.

Purpose of the Study:

• To describe the distribution of P-glycoprotein activity in lymphocytes of healthy individuals.
• To investigate the influence of sex and age on P-glycoprotein activity.
• To establish a population-based model for P-glycoprotein activity.

Main Methods:

• Lymphocyte P-glycoprotein activity was measured using the Rhodamine 123 efflux assay.
• Flow cytometry was employed to quantify P-glycoprotein activity.
• Verapamil, a P-glycoprotein inhibitor, was used to validate the assay.

Main Results:

• P-glycoprotein activity ranged from 1.04 to 3.79, with a bimodal distribution in the population.
• The observed distribution was modeled as F = 0.70 N (2.11; 0.43) + 0.30 N(3.29; 0.26).
• No significant correlation was found between age and P-glycoprotein activity; men showed a trend towards higher activity.

Conclusions:

• Lymphocyte P-glycoprotein activity exhibits significant inter-individual variability, best represented by a bimodal distribution.
• This variability is largely independent of age but shows a slight sex-related difference.
• Characterizing P-gp functionality is essential for developing individualized pharmacological treatments considering pharmacokinetics and pharmacodynamics.